KALV KalVista Pharmaceuticals Inc: רווח למניה בשנים עשר החודשים האחרונים

KalVista Pharmaceuticals (KALV) is attracting experts in global drug commercialization while maintaining a stable R&D core. The business is non-cyclical, as demand is driven by medical necessity. The rolling 12-month earnings per share trend clearly demonstrates the current trajectories, and -3.97 describes the current status of the metric. The company is recognized as a pioneer in hereditary angioedema therapy, developing unique oral treatments.
פילוחים אנליטיים ודוחות נתונים של חברת KalVista Corp (KALV)

For the biotech business of KalVista Pharmaceuticals (KALV), which is awaiting approval of sebetralstat, the company's TTM net income per share serves as a key indicator of capitalization efficiency. This metric aggregates annual profit distributed across the total share issuance, allowing for an assessment of the real return on each share and the determination of the asset's financial cushion before entering the market with a new oral product.